Acta Med Okayama

1. AKAGI N, Kanematsu A, Shigesaka K, Shimatani K, et al
   Prostate Biopsy May Not Be Indicated Early after Bacillus Calmette Guerin Treatment.
   Acta Med Okayama. 2024;78:9-13.
   

   >> Share

   
   

   
   Anticancer Res

2. YU SH, Wang CY, Wang SS, Li JR, et al
   Comparing Clinical Efficacy of Different Bacillus Calmette-Guerin Strains in Patients With T1 High Grade Bladder Cancer.
   Anticancer Res. 2024;44:1299-1307.
   

   >> Share

   
   

   
   Arch Toxicol

3. CHIEN TM, Yang CW, Yen CH, Yeh BW, et al
   Excavatolide C/cisplatin combination induces antiproliferation and drives apoptosis and DNA damage in bladder cancer cells.
   Arch Toxicol. 2024 Feb 29. doi: 10.1007/s00204-024-03699.
   

   >> Share

   
   

   
   Asian Pac J Cancer Prev

4. ELSAYED AM, Mahmoud EI, Salem MM, Khairy RA, et al
   Immunohistochemical Expression of Claudin-1 and Claudin-4 in Urothelial Carcinoma of the Urinary Bladder.
   Asian Pac J Cancer Prev. 2024;25:637-646.
   

   >> Share

   
   

   
   Biol Direct

5. SHEN D, Kang S
   Comprehensive analysis of mitochondria-related genes indicates that PPP2R2B is a novel biomarker and promotes the progression of bladder cancer via Wnt signaling pathway.
   Biol Direct. 2024;19:17.
   

   >> Share

   
   

   
   Biomed Pharmacother

6. FAN J, Chen B, Luo Q, Li J, et al
   Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer.
   Biomed Pharmacother. 2024;173:116312.
   

   >> Share

   
   

   
   Biomol Biomed

7. PANG ZQ, Wang JS, Wang JF, Wang YX, et al
   JAM3 is a potential risk biomarker for predicting prognosis and immune cell infiltration by regulating epithelial-mesenchymal transition in bladder cancer.
   Biomol Biomed. 2024 Feb 23. doi: 10.17305/bb.2024.9979.
   

   >> Share

   
   

   
   BJU Int

8. HAAS M, Engelmann SU, Mayr R, Gossler C, et al
   A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer.
   BJU Int. 2024 Feb 26. doi: 10.1111/bju.16298.
   

   >> Share

   
   
9. TEMPO JA, Sii S, Ischia J, Bolton DM, et al
   Lessons from a population-based bladder cancer registry: exploring why survival is not improving.
   BJU Int. 2024 Feb 26. doi: 10.1111/bju.16286.
   

   >> Share

   
   

   
   BMC Cancer

10. HUANG LH, Chen CS, Li JR, Chiu KY, et al
    The impact of squamous cell transformation on the prognosis of patients treated with radical nephroureterectomy.
    BMC Cancer. 2024;24:247.
    

    >> Share

    
    

    
    BMC Infect Dis

11. CHEN Q, Tan S, Long S, Wang K, et al
    Vagococcus fluvialis isolation from the urine of a bladder cancer patient: a case report.
    BMC Infect Dis. 2024;24:261.
    

    >> Share

    
    

    
    Cancer Res Commun

12. BITTING RL, Tooze JA, Goodman M, Vile DC, et al
    Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma.
    Cancer Res Commun. 2024;4:530-539.
    

    >> Share

    
    

    
    Cancer Sci

13. MUHUITIJIANG B, Zhou J, Zhou R, Zhang Z, et al
    Development and experimental validation of an M2 macrophage and platelet-associated gene signature to predict prognosis and immunotherapy sensitivity in bladder cancer.
    Cancer Sci. 2024 Feb 29. doi: 10.1111/cas.16113.
    

    >> Share

    
    
14. LIU G, Jin K, Liu Z, Su X, et al
    Integration of CD4(+) T cells and molecular subtype predicts benefit from PD-L1 blockade in muscle-invasive bladder cancer.
    Cancer Sci. 2024 Feb 25. doi: 10.1111/cas.16119.
    

    >> Share

    
    

    
    Cancers (Basel)

15. ALBERCA-DEL ARCO F, Prieto-Cuadra D, Santos-Perez de la Blanca R, Saez-Barranquero F, et al
    New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine.
    Cancers (Basel). 2024;16:803.
    

    >> Share

    
    
16. KRAVCHUK AP, Wolff I, Gilfrich C, Wirtz RM, et al
    Urine-Based Biomarker Test Uromonitor((R)) in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer-A Systematic Review and Meta-Analysis of Diagnostic Test Performance.
    Cancers (Basel). 2024;16:753.
    

    >> Share

    
    

    
    Cell Mol Biol Lett

17. XU C, Zhou J, Zhang X, Kang X, et al
    N(6)-methyladenosine-modified circ_104797 sustains cisplatin resistance in bladder cancer through acting as RNA sponges.
    Cell Mol Biol Lett. 2024;29:28.
    

    >> Share

    
    

    
    Cell Signal

18. LUO H, Wang Z
    Pan-cancer analysis reveals potential immunological and prognostic roles of COA6 in human cancers and preliminary exploration of COA6 in bladder cancer.
    Cell Signal. 2024;117:111111.
    

    >> Share

    
    

    
    Clin Transl Sci

19. HU P, Dai HI, Bourdage J, Zhou D, et al
    Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.
    Clin Transl Sci. 2024;17:e13730.
    

    >> Share

    
    

    
    Commun Biol

20. ZHANG R, Jiang W, Wang G, Zhang Y, et al
    Parkin inhibits proliferation and migration of bladder cancer via ubiquitinating Catalase.
    Commun Biol. 2024;7:245.
    

    >> Share

    
    

    
    Cureus

21. WESOLOW JT
    Ogilvie's Syndrome in a Male With Bladder Cancer.
    Cureus. 2024;16:e55097.
    

    >> Share

    
    

    
    Curr Oncol

22. MINATO A, Furubayashi N, Nagata Y, Tomoda T, et al
    Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
    Curr Oncol. 2024;31:862-871.
    

    >> Share

    
    
23. MORIA FA, Park CL, Eigl BJ, Macfarlane R, et al
    A Real-World Retrospective Analysis of the Management of Advanced Urothelial Carcinoma in Canada.
    Curr Oncol. 2024;31:704-722.
    

    >> Share

    
    
24. ENDO Y, Akatsuka J, Takeda H, Hasegawa H, et al
    Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions.
    Curr Oncol. 2024;31:759-768.
    

    >> Share

    
    

    
    Curr Opin Urol

25. CALLERIS G, von Deimling M, Kesch C, Soria F, et al
    Definitions, outcomes and perspectives for oligometastatic bladder cancer: towards a standardized terminology.
    Curr Opin Urol. 2024 Mar 1. doi: 10.1097/MOU.0000000000001170.
    

    >> Share

    
    

    
    Diagnostics (Basel)

26. HE K, Meng X, Wang Y, Feng C, et al
    Progress of Multiparameter Magnetic Resonance Imaging in Bladder Cancer: A Comprehensive Literature Review.
    Diagnostics (Basel). 2024;14:442.
    

    >> Share

    
    

    
    Eur Urol

27. VAN DER KWAST TH, Bubendorf L, Cheng L
    International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer: Main Conclusions and Recommendations.
    Eur Urol. 2024 Feb 26:S0302-2838(24)00080-0. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    

    
    Front Biosci (Landmark Ed)

28. QIU X, Jiang Z, Luo Y, Tian D, et al
    PPP3CB Inhibits Cell Proliferation and the Warburg Effect in Bladder Cancer by Blocking PDHK1.
    Front Biosci (Landmark Ed). 2024;29:48.
    

    >> Share

    
    

    
    Front Oncol

29. ZHOU X, Xue F, Li T, Xue J, et al
    Exploration of potential biomarkers for early bladder cancer based on urine proteomics.
    Front Oncol. 2024;14:1309842.
    

    >> Share

    
    

    
    Future Oncol

30. HOFFMAN-CENSITS J, Grivas P, Powles T, Hawley J, et al
    The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
    Future Oncol. 2024;20:179-190.
    

    >> Share

    
    

    
    Hum Vaccin Immunother

31. HUANG Y, Chen Z, Shen G, Fang S, et al
    Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis.
    Hum Vaccin Immunother. 2024;20:2318815.
    

    >> Share

    
    

    
    In Vivo

32. MINATO A, Murooka K, Okumura Y, Takaba T, et al
    Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology.
    In Vivo. 2024;38:873-880.
    

    >> Share

    
    

    
    Int Braz J Urol

33. PULIATTI S, Ferretti S, Penaranda NR, Eissa A, et al
    Applicability and feasibility of robot-assisted cystectomy and intracorporeal urinary diversion in a patient with right renal pelvic ectopia.
    Int Braz J Urol. 2024;50:227-228.
    

    >> Share

    
    

    
    Int J Mol Sci

34. VUKOVIC M, Chamlati JM, Hennenlotter J, Todenhofer T, et al
    Interleukin-1beta/Interleukin (IL)-1-Receptor-Antagonist (IL1-RA) Axis in Invasive Bladder Cancer-An Exploratory Analysis of Clinical and Tumor Biological Significance.
    Int J Mol Sci. 2024;25:2447.
    

    >> Share

    
    
35. TORRES-BUSTAMANTE MI, Vazquez-Urrutia JR, Solorzano-Ibarra F, Ortiz-Lazareno PC, et al
    The Role of miRNAs to Detect Progression, Stratify, and Predict Relevant Clinical Outcomes in Bladder Cancer.
    Int J Mol Sci. 2024;25:2178.
    

    >> Share

    
    

    
    Int Wound J

36. ZHONG L, Wang F
    Comparative analysis of wound healing techniques in postoperative bladder cancer patients.
    Int Wound J. 2024;21:e14820.
    

    >> Share

    
    

    
    J Mater Chem B

37. WU Y, Gu X, Chen X, Cui Y, et al
    Hydrogel: a new material for intravesical drug delivery after bladder cancer surgery.
    J Mater Chem B. 2024 Mar 1. doi: 10.1039/d3tb02837.
    

    >> Share

    
    

    
    J Natl Compr Canc Netw

38. YEARY KHK, Yu H, Kuliszewski MG, Li Q, et al
    Outcomes of a Dietary Intervention to Reduce Bladder Cancer Recurrence and Progression in Survivors of Non-Muscle-Invasive Bladder Cancer.
    J Natl Compr Canc Netw. 2024 Feb 26:1-9. doi: 10.6004/jnccn.2023.7086.
    

    >> Share

    
    

    
    J Robot Surg

39. MCNICHOLAS DP, El-Taji O, Siddiqui Z, Hanchanale V, et al
    Systematic review comparing uretero-enteric stricture rates between open cystectomy with ileal conduit, robotic cystectomy with extra-corporeal ileal conduit and robotic cystectomy with intra corporeal ileal conduit formation.
    J Robot Surg. 2024;18:100.
    

    >> Share

    
    

    
    Medicina (Kaunas)

40. CORVINO A, Basile L, Cocco G, Delli Pizzi A, et al
    Complications Subsequent to Urinary Tract Stent Placement: An Overview Focusing on the Imaging of Cancer Patients.
    Medicina (Kaunas). 2024;60:338.
    

    >> Share

    
    

    
    Mol Med Rep

41. LI C, Wang Z, Feng N, Dong J, et al
    [Retracted] Human HLA?F adjacent transcript 10 promotes the formation of cancer initiating cells and cisplatin resistance in bladder cancer.
    Mol Med Rep. 2024;29:63.
    

    >> Share

    
    

    
    Natl Sci Rev

42. HOU DY, Zhang NY, Wang L, Lv MY, et al
    Inducing mitochondriopathy-like damages by transformable nucleopeptide nanoparticles for targeted therapy of bladder cancer.
    Natl Sci Rev. 2024;11:nwae028.
    

    >> Share

    
    

    
    Onco Targets Ther

43. 
    LncRNA HCP5 Promotes Cell Invasion and Migration by Sponging miR-29b-3p in Human Bladder Cancer [Retraction].
    Onco Targets Ther. 2024;17:159-160.
    

    >> Share

    
    

    
    Oncol Ther

44. BUONERBA C, Ingenito C, Di Trolio R, Cappuccio F, et al
    Unraveling the Dietary Puzzle: Exploring the Influence of Diet, Nutraceuticals, and Supplements on Bladder Cancer Risk, Outcomes, and Immunotherapy Efficacy: Insights from the BLOSSOM Study and Beyond.
    Oncol Ther. 2024 Feb 28. doi: 10.1007/s40487-024-00266.
    

    >> Share

    
    

    
    Oncotarget

45. CARDILLO TM, Zalath MB, Arrojo R, Sharkey RM, et al
    Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.
    Oncotarget. 2024;15:144-158.
    

    >> Share

    
    

    
    Pathologie (Heidelb)

46. STOLL AK, Koll FJ, Eckstein M, Reis H, et al
    [Histomolecular classification of urothelial carcinoma of the urinary bladder : From histological phenotype to genotype and back].
    Pathologie (Heidelb). 2024;45:106-114.
    

    >> Share

    
    

    
    PET Clin

47. OLDAN JD, Schroeder JA, Hoffman-Censits J, Rathmell WK, et al
    PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers.
    PET Clin. 2024;19:197-206.
    

    >> Share

    
    

    
    Scand J Urol

48. KORNER SK, Dreyer T, Carus A, Dohn LH, et al
    DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer.
    Scand J Urol. 2024;59:39-46.
    

    >> Share

    
    

    
    Scott Med J

49. QIN F, Wu J
    Impact of sarcopenia on outcomes of bladder cancer undergoing radical cystectomy: A systematic review and meta-analysis.
    Scott Med J. 2024 Feb 29:369330241234690. doi: 10.1177/00369330241234690.
    

    >> Share

    
    

    
    Urol Oncol

50. BENDERSKA-SODER N, Ecke T, Kleinlein L, Roghmann F, et al
    Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer.
    Urol Oncol. 2024 Feb 24:S1078-1439(24)00041.
    

    >> Share

    
    
51. ZHOU Z, Zou L, Guan Y, Jiang L, et al
    Survivin as a potential biomarker in the diagnosis of bladder cancer: A systematic review and meta-analysis.
    Urol Oncol. 2024 Feb 27:S1078-1439(24)00019.
    

    >> Share

    
    

    
    Vaccines (Basel)

52. FAN Z, Deng J, Wang Y, Fan X, et al
    Bladder Cancer: Immunotherapy and Pelvic Lymph Node Dissection.
    Vaccines (Basel). 2024;12:150.
    

    >> Share

    
    

    
    World J Urol

53. URABE F
    Letter to the editor for the article "Prognostic factors of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma".
    World J Urol. 2024;42:101.
    

    >> Share

    
    
54. BAHLBURG H, Tully KH, Bach P, Butea-Bocu MC, et al
    Improvements in urinary symptoms, health-related quality of life, and psychosocial distress in the early recovery period after radical cystectomy and urinary diversion in 842 German bladder cancer patients: data from uro-oncological rehabilitation.
    World J Urol. 2024;42:111.
    

    >> Share

    
    
55. SONG Y, Xu T
    Neoadjuvant combination therapy (immunotherapy and chemotherapy) and treatment-related biomarkers in upper tract urothelial carcinoma.
    World J Urol. 2024;42:110.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share